ArticleFrontiers in medicine2026
Anti-Rubella antibodies seroprevalence among pregnant women in South-Western Romania.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Rubella infection during pregnancy poses significant risks, including congenital rubella syndrome (CRS), miscarriage, and fetal death. Vaccination programs have reduced rubella incidence globally, but regional differences in coverage and immunity persist. The objective of the study was to assess the seroprevalence of anti-rubella IgM and IgG antibodies among pregnant women in South-Western Romania, with a focus on temporal trends, demographic factors, and the impact of vaccination eligibility. Methods: This observational, cross-sectional study included pregnant women screened for TORCH infections at the County Clinical Emergency Hospital of Craiova, Romania, during two periods: 2013-2016 and 2019-2022. Serum samples were tested for anti-rubella IgM and IgG antibodies. Participants were stratified by age, area of residence (rural/urban), and eligibility for rubella vaccination based on birth year. Results: A total of 3,268 samples were analyzed. The seroprevalence of acute rubella infection (IgM positive) was low and slightly decreased from 0.54% (2013-2016) to 0.50% (2019-2022), with the most notable decrease in rural areas and among women aged 21-25 years. The overall seroprevalence of protective IgG antibodies was stable (88.28% vs. 88.91%), but remained below the WHO target of 95%. IgG seroprevalence increased among the youngest (<20 years) and 31-35 years age groups, particularly in rural areas, suggesting improved vaccination coverage and natural immunity from past outbreaks. Mapping in Dolj County revealed high seroprevalence near major cities. Discussion: Despite improvements, the relatively low IgG seroprevalence in South-Western Romania highlights the need to reinforce vaccination campaigns, especially in rural areas and among family physicians. Enhanced education and access to vaccination are essential to achieve the WHO eradication target and prevent CRS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.